Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients

Cachexia Clinical Trial

Official title:

Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01015274
• Other study ID #: 09-150
• Secondary ID: 1R43AR054993-01A
• Status: Completed
• Start date: October 2009

Study information

• Verified date: July 2011
• Source: The University of Texas Medical Branch, Galveston
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The long-term objective of this research is to develop a non-invasive approach for early assessment of which patients are at high risk for future development of skeletal muscle atrophy. The investigators hypothesize that the rate constant for the terminal portion of the isotope decay curve following ingestion of a single oral dose of deuterated-3-methylhistidine (D-3MH) provides an accurate measure of this increased risk and that this rate constant can be measured non-invasively from timed spot urine samples.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 30 Years to 75 Years

Eligibility

Inclusion Criteria:

• Male

• 30-75 years old

• Body Mass Index (BMI) <27 kg/m2

Exclusion Criteria:

• Uncontrolled hypertension

• Glomerular filtration rate less than 60 mL/min/1.73 m2

• History of recurrent gastrointestinal bleeding

• Unable or unwilling to provide informed consent

• Ongoing anti-coagulant therapy

Related Conditions & MeSH terms

• Cachexia

Locations

Country	Name	City	State
United States	University of Texas Medical Branch	Galveston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
The University of Texas Medical Branch, Galveston

Country where clinical trial is conducted

United States,